Pharmacology and signaling properties of epidermal growth factor receptor isoforms studied by bioluminescence resonance energy transfer

Molecular Pharmacology

Volumn 71, Issue 2, 2007, Pages 508-518

  Schiffer, Hans H ^a   Reding, Esther C ^a   Fuhs, Stephen R ^a   Lu, Qing ^a   Piu, Fabrice ^a   Wong, Steven ^a   Littler, Pey Lih H ^a   Weiner, Dave M ^a   Keefe, William ^a   Tan, Phil K ^a   Nash, Norman R ^a   Knapp, Anne E ^a   Olsson, Roger ^a   Brann, Mark R ^a  

^a ACADIA PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; ISOPROTEIN; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL]ACRYLAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ARTICLE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CONTROLLED STUDY; DRUG ACTIVITY; HUMAN; HUMAN CELL; IC 50; LUNG CANCER; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; SOMATIC MUTATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL LINE; DRUG RESISTANCE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; LUMINESCENT MEASUREMENTS; LUMINESCENT PROTEINS; LUNG NEOPLASMS; MUTATION; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 33846465419     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.027656     Document Type: Article

References (37)

1. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, et al. (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20:4292-4302.
2. Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R, Sharma SV, Brannigan BW, Mohapatra G, Settleman J, et al. (2005) Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 37:1315-1316.
3. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, et al. (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643-655.
4. Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, Milanov ZV, Atteridge CE, Biggs WH 3rd, Edeen PT, et al. (2005) Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 102:11011-11016.
5. Dean M, Fojo T, and Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5:275-284.
6. Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, Hook KE, Keller PR, Leopold WR, Loo JA, et al. (1998) Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci USA 95:12022-12027.
7. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [published erratum appears in J Clin Oncol 22:4811, 2004]. J Clin Oncol 21:2237-2246.
8. Gales C, Rebois RV, Hogue M, Trieu P, Breit A, Hebert TE, and Bouvier M (2005) Real-time monitoring of receptor and G-protein interactions in living cells. Nat Methods 2:177-184.
9. Goldberg RM (2005) Cetuximab. Nat Rev Drug Discov Suppl:S10-S11.
10. Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR, et al. (2005) Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2:e313.
11. Habib AA, Chun SJ, Neel BG, and Vartanian T (2003) Increased expression of epidermal growth factor receptor induces sequestration of extracellular signal-related kinases and selective attenuation of specific epidermal growth factor-mediated signal transduction pathways. Mol Cancer Res 1:219-233.
12. Hayes N, Howard-Cofield E, and Gullick W (2004) Green fluorescent protein as a tool to study epidermal growth factor receptor function. Cancer Lett 206:129-135.
13. Herbst RS, Fukuoka M, and Baselga J (2004) Gefitinib-a novel targeted approach to treating cancer. Nat Rev Cancer 4:956-965.
14. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, et al. (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267-3279.
15. Hynes NE and Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341-354.
16. Jiang J, Greulich H, Janne PA, Sellers WR, Meyerson M, and Griffin JD (2005) Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res 65:8968-8974.
17. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, and Halmos B (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786-792.
18. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, et al. (2005) Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102:7665-7670.
19. Laursen LS and Oxvig C (2005) Real-time measurement in living cells of insulin-like growth factor activity using bioluminescence resonance energy transfer. Biochem Pharmacol 69:1723-1732.
20. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139.
21. Minna JD and Dowell J (2005) Erlotinib hydrochloride. Nat Rev Drug Discov Suppl: S14-S15.
22. Olive DM (2004) Quantitative methods for the analysis of protein phosphorylation in drug development. Expert Rev Proteomics 1:327-341.
23. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (Wash DC) 304:1497-1500.
24. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al. (2004a) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306-13311.
25. Pao W and Miller VA (2005) Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 23:2556-2568.
26. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, and Varmus H (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73.
27. Pao W, Miller VA, Venkatraman E, and Kris MG (2004b) Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt? J Natl Cancer Inst 96:1117-1119.
28. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P, and Bonomi P (2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22:3238-3247.
29. Perez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Sureda BM, von Pawel J, Temel J, Siena S, Soulieres D, et al. (2005) HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 10:345-356.
30. Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103:211-225.
31. Schlessinger J (2002) Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 110:669-672.
32. Schulze WX, Deng L, and Mann M (2005) Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 1:2005 0008.
33. Sordella R, Bell DW, Haber DA, and Settleman J (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science (Wash DC) 305:1163-1167.
34. Sorkin A, McClure M, Huang F, and Carter R (2000) Interaction of EGF receptor and grb2 in living cells visualized by fluorescence resonance energy transfer (FRET) microscopy. Curr Biol 10:1395-1398.
35. Spalding TA, Burstein ES, Brauner-Osborne H, Hill-Eubanks D, and Brann MR (1995) Pharmacology of a constitutively active muscarinic receptor generated by random mutagenesis. J Pharmacol Exp Ther 275:1274-1279.
36. Tateishi M, Ishida T, Mitsudomi T, Kaneko S, and Sugimachi K (1990) Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res 50:7077-7080.
37. Tyagi P (2005) Updated Data from the Iressa Survival in Lung Cancer Trial. Clin Lung Cancer 6:340-342.